Dr. Faith Davies is the Director of Perlmutter Cancer Center’s Clinical Myeloma Program. Previously, she was the medical director of the Myeloma Institute at the University of Arkansas for Medical Science. Her current research focuses on the genetic, biologic and radiologic theranostic markers to improve outcomes for patients with myeloma. Dr. Davies received her Bachelor of Medicine and medical degrees from the University of Wales College of Medicine and completed her hematology speciality training in the United Kingdom. She completed fellowships at the Royal College of Pathologists and American College of Physicians, and also at the University of London.
Dr. Davies has focused for nearly two decades on the biology and treatment of multiple myeloma. Throughout her extensive career, her research has examined potential new drugs and new genetic technologies and their applications to myeloma. Her laboratory work is aimed at identifying biologically based therapeutic targets in myeloma that are amenable to small molecule interventions and translating those laboratory findings into the clinical arena with a focus on individualized treatment.
Dr. Davies is a member of the American Society of Hematology, the American Association for Cancer Research, the British Society of Haematology, the Royal College of Physicians, UK, and the Royal College of Pathologists, UK.
She is widely published in leading peer-reviewed journals, including New England Journal of Medicine, Blood, Journal of Clinical Oncology, Leukemia and Lancet-Oncology. Dr. Davies is on the advisory boards for Celgene, Takeda, Amgen and BMS.